Skip to content
Meru Sandbox
Search
Menu
Back to Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.
Yu-Jiun Chan
Contributions
Showing
1 - 1
out of
1
Author
Published August 1, 2015